Home > Insider Trading > Filing (0001209191-13-034478)

Filing Details

Accession Number:: 0001209191-13-034478
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-07-01 19:50:28
Reporting Period:: 2013-07-01

Filing Date:: 2013-07-01
Accepted Time:: 2013-07-01 19:50:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1401708	Nanostring Technologies Inc	NSTG	Biological Products, (No Disgnostic Substances) (2836)	200094687

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1431437	Clarus Ventures Ii, Llc	C/O Of Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431439	Clarus Ventures Ii Gp, L.p.	C/O Of Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431443	Clarus Lifesciences Ii, L.p.	C/O Of Clarus Ventures, Llc 101 Main Street, Suite 1210 Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-07-01	2,249,053	$0.00	2,249,053	No	4	C	Direct
Common Stock	Acquisiton	2013-07-01	812,045	$0.00	3,061,098	No	4	C	Direct
Common Stock	Acquisiton	2013-07-01	148,342	$0.00	3,209,440	No	4	C	Direct
Common Stock	Acquisiton	2013-07-01	750,000	$10.00	3,959,440	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2013-07-01	2,249,053	$0.00	2,249,053	$0.00
Common Stock	Series D Preferred Stock	Disposition	2013-07-01	812,045	$0.00	812,045	$0.00
Common Stock	Series E Preferred Stock	Disposition	2013-07-01	148,342	$0.00	148,342	$0.00
Common Stock	Serries D Preferred Warrant (Right to Buy)	Disposition	2013-07-01	162,408	$8.45	162,408	$8.45
Common Stock	Common Stock Warrant (Right to Buy)	Acquisiton	2013-07-01	162,408	$8.45	162,408	$8.45

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Direct
0		No	4	C	Direct
0		No	4	C	Direct
0	2018-11-01	No	4	C	Direct
162,408	2018-11-01	No	4	C	Direct

Footnotes

Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus Lifesciences II, L.P. ("Clarus"), may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each of Nicholas Galakatos, a member of the board of directors, and Messrs. Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus.
Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest.
The Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock converted into Common Stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date.
The Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock converted into Common Stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock.